Sai Life Sciences hiring FY27 plans signal strong growth in India’s CRDMO sector. Sai Life Sciences announced it will recruit more than 700 scientific, technical, and management professionals during 2026–27. The expansion supports rising global demand for integrated drug discovery, development, and manufacturing services.
The company will add talent across medicinal chemistry, biology, DMPK, process and analytical development, formulation development, manufacturing, quality, peptides, business development, and program management. As global innovator companies outsource increasingly complex programs, Sai Life Sciences aims to strengthen its scientific depth and operational scale.
Focus on High-Caliber Scientific Talent
Importantly, the recruitment drive will target top scientists from leading institutions in India and abroad. According to CEO and Managing Director Krishna Kanumuri, the Indian CRDMO industry stands at an inflection point.
He noted that global supply-chain rebalancing and the need for resilient development partners favor India. Therefore, the company is preparing its infrastructure, digital systems, and quality platforms to meet higher scientific expectations.
Moreover, Kanumuri emphasized that Indian scientists worldwide now have an opportunity to work on globally significant programs without leaving India. This growth phase offers exposure to advanced research while maintaining rigorous scientific standards.
Supporting Advanced Drug Development Capabilities
The new hires will strengthen key growth areas. These include complex small-molecule synthesis, high-throughput experimentation, data-enabled drug discovery, and late-stage CMC and commercial manufacturing scale-up. As demand increases, the company aims to deliver seamless end-to-end solutions to global pharmaceutical and biotechnology partners.
In addition, Sai Life Sciences has launched a global alumni engagement platform. It is also expanding leadership development and internal mobility programs to support long-term career growth.
Expanding Global Footprint and Hyderabad Hub
Sai Life Sciences operates across India, the UK, and the US. Its Manchester site focuses on process R&D, while its Boston Biology facility supports early discovery collaborations and client engagement. However, most of the new roles will be based in Hyderabad, home to its largest integrated R&D campus.
Currently, the company employs more than 3,400 scientists and professionals. With this planned hiring, Sai Life Sciences reinforces its position as a leading global CRDMO partner while accelerating India’s role in advanced pharmaceutical innovation.
Read Also: Brenus Pharma Highlights STC-1010 Data at AACR Immuno-Oncology 2026
